Beheshti, M; Rinnerthaler, G; Farbod, A; Hitzl, W; Egle, D; Gampenrieder, SP; Bartsch, R; Balic, M; Greil, R; Gnant, M; Pirich, C.
Predictive role of baseline [18F]FDG PET/CT quantitative parameters for response to neoadjuvant treatment with atezolizumab, trastuzumab, pertuzumab and epirubicin in HER2-positive early breast cancer - a substudy of the ABCSG-52/ATHENE phase II trial
EUR J NUCL MED MOL I. 2024; 51: S481-S482.
[Poster]
Web of Science